Quantessence Capital’s Myriad Genetics MYGN Stock Holding History

Quantessence Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,113	Closed	-$138K	–	115
2025 Q3	$138K	Buy	+19,113	New	+$113K	0.04%	166

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quantessence Capital's MYGN Position: Q4 2025 in Review

Quantessence Capital sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 19,113 shares — an estimated $138K sold.

Quantessence Capital first reported a position in MYGN in Q3 2025 and held it in 1 quarter. The position peaked at $138K in Q3 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

Quantessence Capital reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
Quantessence Capital sold 19,113 Myriad Genetics shares in Q4 2025, an estimated $138K.
Quantessence Capital first reported a position in Myriad Genetics in Q3 2025 and held it in 1 quarter.
Quantessence Capital's Myriad Genetics position peaked at $138K in Q3 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Quantessence Capital's 13F filing for Q4 2025, filed 17 Feb 2026.